US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% SNDK $1,704.16 ▼-0.92% AAPL $332.89 ▼-0.24%
FinancialContent

Articles published by PsychoGenics Inc.

News headline image
PsychoGenics Awarded an NIH Contract to Test and Identify Novel Therapeutics for Pain
From PsychoGenics Inc.
Via Business Wire
News headline image
PsychoGenics Inc. Awarded $3 Million SBIR Grant to Employ Its AI-Enabled Platforms to Find Treatments for Rare Disorders
From PsychoGenics Inc.
Via Business Wire
News headline image
PsychoGenics Announces Exclusive Global License for an IND-Ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders
From PsychoGenics Inc.
Via Business Wire
News headline image
PsychoGenics Launches an Updated Corporate Identity and Brand
From PsychoGenics Inc.
Via Business Wire
News headline image
PsychoGenics and Collaborations Pharmaceuticals awarded a $1M grant to use AI platforms to design new drugs for mental health disorders
From PsychoGenics Inc.
Via Business Wire
News headline image
PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery
From PsychoGenics Inc.
Via Business Wire
News headline image
PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics
From PsychoGenics Inc.
Via Business Wire
Tickers KRTX
News headline image
PsychoGenics Strengthens Executive Team to Boost CNS Drug Discovery and CRO Capabilities
From PsychoGenics Inc.
Via Business Wire
News headline image
PsychoGenics’ High Data Security Standards Are Certified by The NIH
From PsychoGenics Inc.
Via Business Wire
News headline image
PsychoGenics Appoints Dr. Stephen Morairty as Vice President, Translational Neuroscience and Jean-Sebastien Valois as Vice President, Engineering and AI Development
From PsychoGenics Inc.
Via Business Wire
News headline image
PsychoGenics Chief Innovation Officer Honored for Scientific Excellence
From PsychoGenics Inc.
Via Business Wire